Intravenous golimumab in rheumatoid arthritis

被引：9

作者：

Cohen, Marc D. ^{[1
]}

Keystone, Edward C. ^{[2
,3
]}

机构：

[1] Mayo Clin, Denver, CO 80218 USA

[2] Univ Toronto, Toronto, ON, Canada

[3] Mt Sinai Hosp, Toronto, ON M5T 3L9, Canada

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2014年 / 10卷 / 07期

关键词：

anti-TNF-; antibodies; golimumab; rheumatoid arthritis treatment; safety of TNF- inhibition; TNF-; inhibition; ALPHA MONOCLONAL-ANTIBODY; NECROSIS-FACTOR-ALPHA; DOUBLE-BLIND; PHASE-III; ANKYLOSING-SPONDYLITIS; METHOTREXATE THERAPY; SAFETY; EFFICACY; PHARMACOKINETICS;

D O I：

10.1586/1744666X.2014.918847

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Intravenous golimumab in a dosage of 2 mg/kg, initially given every 4 weeks but then every 8 weeks, in addition to methotrexate, is effective in the treatment of patients with rheumatoid arthritis. This weight-based infusion is administered over thirty minutes with an acceptable safety profile. Since it is a relatively new formulation, more time will be required to assess its specific role in the rheumatologists' armamentarium and to appreciate more fully its long-term safety.

引用

页码：823 / 830

页数：8

共 50 条

[41] Importance of Steady-State Trough Concentrations After Intravenous Golimumab with Concomitant Methotrexate in Subjects with Active Rheumatoid Arthritis
Leu, J. H.
Xu, Z.
Hu, C.
Mendelsohn, Alan
Ford, J.
Davis, Hugh M.
Zhou, H.
ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S554 - S554
[42] IMPORTANCE OF STEADY-STATE TROUGH CONCENTRATIONS AFTER INTRAVENOUS GOLIMUMAB WITH CONCOMITANT METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
Leu, J. H.
Xu, Z.
Hu, C.
Mendelsohn, A.
Ford, J.
Davis, H. M.
Zhou, H.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 868 - 868
[43] Patient Characteristics and Medication Utilization Patterns of Infliximab-Treated Rheumatoid Arthritis Patients Subsequently Transitioned to Intravenous Golimumab
Ellis, Lorie A.
DeHoratius, Raphael J.
Kafka, Shelly
Varker, Helen
Brouillette, Matthew
Malangone-Monaco, Elisabetta
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[44] Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab
Matsuno, Hiroaki
Katayama, Kou
MODERN RHEUMATOLOGY, 2017, 27 (02) : 246 - 251
[45] COST-EFFECTIVENESS ANALYSIS OF GOLIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
Desai, R. J.
Rao, J.
Biddle, A. K.
VALUE IN HEALTH, 2012, 15 (04) : A39 - A39
[46] INTRAVENOUS GOLIMUMAB INHIBITS RADIOGRAPHIC PROGRESSION AND MAINTAINS CLINICAL EFFICACY AND SAFETY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY: 2-YEAR RESULTS OF A PHASE 3 TRIAL OF INTRAVENOUS GOLIMUMAB
Weinblatt, M. E.
Bingham, C. O., III
Mendelsohn, A. M.
Kim, L.
Lo, K. H.
Noonan, L.
Baker, D.
Westhovens, R.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 939 - 939
[47] EFFECTIVENESS AND SAFETY OF INFLIXIMAB, GOLIMUMAB AND GOLIMUMAB-IV IN RHEUMATOID ARTHRITIS FROM A LONGITUDINAL OBSERVATIONAL REGISTRY
Rahman, Proton
Baer, Philip
Choquette, Denis
Olszynski, Wojciech
Faraawi, Rafat
Bessette, Louis
Baker, Milton
Rai, Raman
Kelsall, John
Lisnevskaia, Larissa
Reis, Jodie
Anderson, Keltie
Rampapakis, Emmanouil
Asin-Milan, Odalis
Lehman, Allen J.
Nantel, Francois
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S44 - S44
[48] The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
Furst, Daniel E.
Kay, Jonathan
Wasko, Mary Chester
Keystone, Edward
Kavanaugh, Arthur
Deodhar, Atul
Murphy, Frederick T.
Magnus, Jeanette H.
Hsia, Elizabeth C.
Hsu, Benjamin
Xu, Stephen
Rahman, Mahboob U.
Doyle, Mittie K.
RHEUMATOLOGY, 2013, 52 (10) : 1845 - 1855
[49] PATIENT CHARACTERISTICS AND GOLIMUMAB UTILIZATION IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS PATIENTS
Tandon, N.
Haas, S.
Bolge, S.
Gunnarsson, C.
VALUE IN HEALTH, 2012, 15 (04) : A48 - A48
[50] Intravenous Golimumab in the Treatment of Juvenile Idiopathic Arthritis and Its Associated Uveitis
Khan, Shawn
Saigal, Khushi
Sheth, Sohum
Maleki, Arash
OCULAR IMMUNOLOGY AND INFLAMMATION, 2024,

← 1 2 3 4 5 →